Chatbot Intervention
Devicea chatbot will be used to monitor depression severity
NCT Number: NCT03990389
The goal of this research is to bridge a significant "effectiveness" gap in the treatment of depression. The investigators have developed a chatbot which will assist in performing measurement-based care (MBC) via Facebook Messenger. Participants will be randomized to either Usual Care or Usual Care with additional Chatbot Care.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
University of Chicago, Chicago, Illinois, United States
The goal of this research is to bridge a significant "effectiveness" gap in the treatment of depression. The investigators will be looking specifically at depressed women soon after they give birth, otherwise known as known as perinatal depression. Measurement-based care (MBC) which involves the use of quantitative assessments for depression screening, diagnosis, and symptom monitoring is recognized as one of the keys to depression management. MBC can be difficult to implement within the clinical setting due to the administrative overhead and close follow-up required. It is reasonable to hypothesize that low rates of MBC adoption are responsible for low rates of adequate depression care.
The investigators have developed an automated conversational agent or "chatbot" (CB) for delivering MBC via Facebook Messenger. The investigators hypothesize that the use of CB-MBC, which combines a conversational interface with state-of-the-art quantitative assessments, will improve depression symptom severity for patients with perinatal depression. If successful, this project will provide primary care physicians with a new and inexpensive method for delivering better and safer care to their patients with depression. This study works to determine the impact of the chatbot in improving depression outcomes for patients under treatment for perinatal depression.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
a chatbot will be used to monitor depression severity
Time frame: 3 months
Measured by the Edinburgh Postnatal Depression Scale (EPDS) Range 0-30 (dimensionless) Risk of depression goes up with an increasing score
Time frame: 3 months
Measured by the Computerized Adaptive Test-Depression Inventory (CAT-DI) and calculated change in Edinburgh Postnatal Depression Scale (EPDS) between Baseline and 3 months.
Edinburgh Postnatal Depression Scale (EPDS) Range 0-30 (dimensionless) Risk of depression goes up with an increasing score
Time frame: 3 months
Measured by the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) questionnaire
Time frame: 3 months
Measured by the Barkin Index of Maternal Functioning
Time frame: 3 months
Measured by Maternal Confidence Questionnaire
Time frame: 3 months
Measured by 1-item medication adherence questionnaire
University of Chicago
Other
Automated Symptom Tracking for Measurement-Based Care of Depression
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03460756
Behavior, Behavioral Symptoms
Glendale, California, United States
View Trial DetailsNCT03228394
Behavior, Behavioral Symptoms
Little Rock, Arkansas, United States
View Trial DetailsNCT02664467
Behavior, Behavioral Symptoms
Lugano, Canton Ticino, Switzerland
View Trial DetailsNCT03646539
Anxiety, Anxiety Disorders
Stanford, California, United States
View Trial Details